Superficial bladder cancer does recur despite bacillus Calmette–Guérin (BCG) instillations—currently the most effective prophylactic therapy. Antifibrinolytic agents seem to enhance the efficacy of ...
The association between allopurinol use and urologic malignancies: A nested case-control study. This is an ASCO Meeting Abstract from the 2020 Genitourinary Cancers Symposium. This abstract does not ...
In patients with non-muscle-invasive bladder cancer, especially those with carcinoma in situ (CIS), most recurrences, progression events, and cystectomies occurred in those with bacillus ...
Intravesical instillation of bacillus Calmette-Guérin (BCG) is most effective in the long term when selected as initial prophylactic treatment to prevent recurrence of superficial bladder cancer, ...
A 65-year-old man with a history of T1 high-grade bladder cancer with CIS underwent successful transurethral resection of bladder tumor (TURBT), without residual tumor on second resection. Given his ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access ...
In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
The US Food and Drug Administration (FDA) has approved the first-in-class interleukin (IL)-15 superagonist nogapendekin alfa inbakicept-pmln (Anktiva), plus bacillus Calmette-Guérin (BCG), for the ...
A 64-year-old man presented with a three-week history of a tender suprapubic mass. His medical history included superficial (stage T1) transitional cell carcinoma of the bladder for which he had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results